Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.

摘要: Ovarian cancer is clinically quiet as it plants seeds of metastases in the peritoneal cavity, even during early stages when there highest potential for cure. The only available biomarker CA125, which has an unacceptably low sensitivity and specificity diagnostic use. Highly sensitive specific tools to further optimize diagnosis treatment are needed. We propose that proteomic technologies have important role play development these tools. Mass spectrometry platforms, such surface-enhanced laser desorption/ionization time-of-flight, may be used mine patient9s serum signatures shed by tumor stroma. Such could serve a tool early-stage disease remission-monitoring later-stage disease. Reverse-phase protein microarrays new microproteomic profile signaling pathways ovarian cancer, thus identifying therapeutic targets while simultaneously suggesting prognostic indicators. Proteomic capacity build upon our genomic clinical understanding moving focal point its microenvironment. This unique vantage allows creation will aid clinicians making rational decisions women with cancer.